Table 1. Diagnostic miRNAs of interest.
| Study (year) | miRNA | Direction of change | Study design | Ref. |
|---|---|---|---|---|
| Chen et al. (2012) | Let-7c | ↓ | PC vs BPH and HCs | [71] |
| Chen et al. (2012) | Let-7e | ↓ | PC vs BPH and HCs | [71] |
| Mahn et al. (2011) | Let-7i | ↑ | mPC vs BPH | [73] |
| Agagolu et al. (2011) | miR-21 | ↑ | PC vs HCs | [72] |
| Moltzahn et al. (2011) | miR-24 | ↓ | PC vs HCs | [69] |
| Mahn et al. (2011) | miR-26a | ↑ | mPC vs BPH | [73] |
| Chen et al. (2012) | miR-30c | ↓ | PC vs BPH and HCs | [71] |
| Moltzahn et al. (2011) | miR-93 | ↑ | PC vs HCs | [69] |
| Moltzahn et al. (2011) | miR-106a | ↑ | PC vs HCs | [69] |
| Bryant et al. (2012) | miR-107 | ↑ | PC vs HCs | [70] |
| Mitchell et al. (2008) | miR-141 | ↑ | mPC | [68] |
| Brase et al. (2011) | miR-141 | ↑ | mPC vs localized | [78] |
| Nguyen et al. (2013) | miR-141 | ↑ | HRPC vs localized | [79] |
| Mahn et al. (2011) | miR-195 | ↑ | mPC vs BPH | [73] |
| Yaman Agaoglu et al. (2011) | miR-221 | ↑ | PC vs HCs | [72] |
| Brase et al. (2011) | miR-375 | ↑ | mPC vs localized | [78] |
| Nguyen et al. (2013) | miR-375 | ↑ | HRPC vs localized | [79] |
| Nguyen et al. (2013) | miR-378 | ↑ | HRPC vs localized | [79] |
| Nguyen et al. (2013) | miR-409-3p | ↑ | HRPC vs localized | [79] |
| Chen et al. (2012) | miR-622 | ↑ | PC vs BPH and HCs | [71] |
↑: Increased expression; ↓: Decreased expression; BPH: Benign prostatic hypertrophy; HC: Healthy control; HRPC: Hormone-refractory prostate cancer; mPC: Metastatic prostate cancer; PC: Prostate cancer.